Actively Recruiting
Molecular Basis of Human Phagocyte Interactions With Bacterial Pathogens
Led by National Institute of Allergy and Infectious Diseases (NIAID) · Updated on 2026-04-07
200
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Human phagocytic cells such as polymorphonuclear leukocytes (PMNs) are readily mobilized to sites of infection and ingest microorganisms by a process known as phagocytosis. The combined effects of reactive oxygen species (ROS) and proteolytic peptides and enzymes released into forming bacterial phagosomes kill most ingested bacteria. However, many human bacterial pathogens have devised means to subvert normal phagocyte responses and the innate immune response and cause severe disease. The overall objective of this study is to elucidate specific features of pathogen-phagocyte interactions that underlie evasion of the innate immune response or contribute to the pathophysiology of disease or inflammatory disorders. Therefore, specific projects will: 1. Identify and characterize specific mechanisms used by pathogenic microorganisms to evade or subvert normal phagocyte responses and therefore cause disease. 2. Investigate phagocyte response mechanisms to specific pathogenic microorganisms. 3. Identify specific bacterial structures and/or (gene) products that dictate differences in phagocyte responses among a range of pathogens so that generalized statements can be made about the pathophysiology of disease states. The studies will be performed using multiple techniques including state-of-the-art equipment for genomics and proteomics strategies to identify target bacterial genes/proteins of interest or those up-regulated in phagocytes. Phagocyte-pathogen interactions will be examined using fluorescence-based real-time assays and video microscopy, confocal and electron microscopy in combination with enzymatic assays for ROS production, routine biochemistry, immunology and cell biology. Implementing these studies will require isolation of phagocytic leukocytes from venous blood of healthy human volunteers. The study population will be all-inclusive except in certain instances where individuals possess genetic defects that impair phagocyte function (e.g., myeloperoxidase-deficiency) or have altered phagocyte function due to outside influences such as recent bacterial or viral infection. The proposed studies will likely provide new information pertinent to understanding host cell-pathogen interactions and the pathophysiology of inflammatory conditions.
CONDITIONS
Official Title
Molecular Basis of Human Phagocyte Interactions With Bacterial Pathogens
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Volunteers must be healthy adults aged 18 years or older
- Participants must have no known medical problems
- Willingness to have blood and/or tissue samples stored for future research
- Generally recruited from NIH employees at Rocky Mountain Laboratories or the local community
- No racial or gender restrictions; all are eligible
- Must fit the definition of healthy adults based on medical screening
You will not qualify if you...
- Children are not eligible to participate
- Pregnant women are excluded
- Individuals with genetic defects impairing phagocyte function, such as myeloperoxidase deficiency, are excluded
- Those with altered phagocyte function due to recent bacterial or viral infection are excluded
- Individuals with below normal hematocrit and hemoglobin levels are excluded
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
NIAID, Rocky Mountain Laboratories
Hamilton, Montana, United States, 59840
Actively Recruiting
Research Team
F
Frank R De Leo, Ph.D.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here